Health ❯ Healthcare ❯ Chronic Diseases ❯ Diabetes

Obesity

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Full results will be presented at next week’s CTAD meeting after the company canceled a planned one-year extension.

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults